Yochai Adir has received personal fees for lecturing and/or consulting from Actelion, Boehringer Ingelheim, Teva, Bayer, GlaxoSmithKline, Roche, Novartis, AstraZeneca, Kamada and UT Pharmaceuticals, and research grants from Actelion, Bayer, Boehringer Ingelheim and GlaxoSmithKline.
Laurent Savale reports grants, personal fees and non-financial support from Actelion, MSD, GlaxoSmithKline, and Bayer.
Sinthia Bosnic-Anticevich reports grants and personal fees from TEVA, and personal fees from Boehringer Ingelheim, AstraZeneca, Sanofi and Mylan.
Tom Kotsimbos has received investigator-initiated study support and clinical trial support from Vertex P/L.
Ralph Schermuly has nothing to disclose.
Bruno Crestani has received personal fees and non-financial support from AstraZeneca and Sanofi; grants, personal fees and non-financial support from Boehringer Ingelheim and Roche; grants from MedImmune; and personal fees from Genzyme.
Peter Dorfmüller, in the past 3 years, has received speaker’s fees from Actelion and MSD, and travel grants from GlaxoSmithKline.
Charlotte Summers’ laboratory received funding from GlaxoSmithKline, Wellcome Trust, Medical Research Council, MedImmune, British Heart Foundation, and the National Institute for Health Research (NIHR) for work performed there.
Ernesto Crisafulli has nothing to disclose.
Paola Rottoli reports personal fees for participation in scientific advisory boards and/or in educational meetings as a speaker from Boehringer Ingelheim, Roche and Teva, and sponsorship for attending international congresses from Roche and Menarini Group.
Nir Peled has acted in an advisory role and has received honoraria from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Foundation Medicine, Guardant360, MSD, Novartis, NovellusDx, Pfizer, Roche and Takeda.
Giora Pillaris a consultant for the following companies: Dayzz, Itamar-Medical, InnoBev, KeepMed. In the past 2 years he has also given lectures supported by Sanofi, Teva and Pfizer.
David Feller-Kopman has received consulting fees from Veracyte, Veran Medical, AstraZeneca, Nuvaira and Merit Endotek. He is also on the Data Safety Monitoring Board for CSA Medical, Uptake Medical and has received research support from BD (SWIFT trial: SN coated PleurX).
Martin Kolb has received grants and personal fees from Roche, Boehringer Ingelheim, GlaxoSmithKline, Gilead, Prometic and Alkermes; grants from Actelion, Respivert and Synairgen; and personal fees from AstraZeneca and Genoa.
James Chalmers has received research grants from GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Pfizer, Grifols, Bayer AG, Polyphor and Insmed; and received consultancy, congress travel or speaker fees from GlaxoSmithKline, Bayer Healthcare, Aradigm corporation, Grifols, Pfizer, Boehringer Ingelheim, Napp and Insmed.
Alyn Morice has received grants and/or personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi Ltd, Merck Sharp & Dohme, Sanofi, Airway Vista 2018 South Korea, Menlo Pharmaceuticals, Pfizer, National Medical Research Council, JOMO-UKCPA, Bellus Health, AIST Congress Italy, SA.MA Congress Service Italy, Association for Respiratory Technology and Physiology, Mederic Edicious SL Spain, SRxA USA, and the National Lung Health Congress 2018 Turkey.
Claudia Dobler has nothing to disclose.
James Walter has nothing to disclose.
Jason Weatherald has received grants from the European Respiratory Society, Canadian Thoracic Society, and Canadian Vascular Network. He has received honoraria, personal fees, and travel support from Actelion Pharmaceuticals and Janssen Canada Inc., as well as personal fees and travel support from Bayer, and personal fees from Novartis.
Zhi-Cheng Jing has nothing to disclose.
Yuichi Tamura has nothing to disclose.
Mordechi Kramer has received lecture fees from Boehringer Ingelheim, Actelion and GlaxoSmithKline.
Zvi Fridlender is a member of scientific advisory boards for Atrin Pharmaceuticals; has been an ad hoc advisor for GlaxoSmithKline, AstraZeneca Israel, Boehringer Ingelheim, Sanofi-Genzyme and Novartis; has received travel grants (for international conferences) from Novartis, GlaxoSmithKline, Boehringer Ingelheim, Rafa and Roche; and has received funding for lectures from GlaxoSmithKline, AstraZeneca Israel, Novartis, Megapharm, Teva, Boehringer Ingelheim, Sanofi-Genzyme and Rafa.
David Shitrit has nothing to disclose.
Eva Polverino has received speaker fess from Bayer, Menarini, Grifols, Zambon, Pfizer, Chiesi, Teva and Shire. She has also received consultant fees from Insmed, Bayer, Polyphor, Zambon and Chiesi, and grant/research support from Chiesi and Grifols.
Michal Shteinberg has received research grants from GlaxoSmithKline, Novartis and Trudell pharma; travel grants from Novartis, Actelion, Boeringer Ingelheim, GlaxoSmithKline and Rafa; speaker's fees from Boeringer Ingelheim, GlaxoSmithKline, AstraZeneca, Teva and Novartis; and advisory fees from GlaxoSmithKline, Boeringer Ingelheim and Horizon pharma. He is a member of the EMBARC group.
Soni Savai Pullamsetti has nothing to disclose.
Walter McNicholas has nothing to disclose.
Marc Miravitlles has received speakers fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, AstraZeneca, Menarini, Rovi, Bial, Zambon, CSL Behring, Grifols and Novartis; consulting fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, CSL Behring, Laboratorios Esteve, Ferrer, Mereo Biopharma, Verona Pharma, TEVA, pH Pharma, Novartis and Grifols; and research grants from GlaxoSmithKline and Grifols.
Stefano Nava has received research grants from Fisher and Paykel and has been a member of scientific board for Philips – Breas.
Pierantonio Lavenziana reports personal fees (consulting, lectures and advisory boards) from Novartis, Chiesi and Boehringer.
Joel Moss has nothing to disclose.
Anh-Tuan Dinh Xuan has received consultancy fees and research project fees from Air Liquide, and personal fees from GlaxoSmithKline, Circassia, Chiesi, Novartis and AstraZeneca.
Michael Kreuter reports grants and fees, to him or his institution, from Roche and Boehringer; personal fees from AstraZeneca, GlaxoSmithKlne, Galapagos and Chiesi.
Steeve Provencher is clinician-scientist of the Fonds de Recherche en Santé du Québec and has received grants from the Canadian Institutes for Health Research, as well as research grants from Actelion Pharmaceuticals, Boehringer-Ingelheim and Resverlogix. He also received consultancy fees from Actelion Pharmaceuticals.
Geert Verleden has received nonpersonal research funding from Chiesi Belgium, FWO Flanders, GlaxoSmithKline Belgium and Broere Foundation, nonpersonal reasearch fees from Sandoz EG and Chiesi, and educational fees from GlaxoSmithKline.
Antoni Torres has received consultancy fees from Pfizer, Poliphor, MSD, ROCHE and Vio Versys.
Rogerio Souza has received lecture and consultancy fees from Bayer, Actelion, Pfizer and GlaxoSmithKline.
Ralph Epaud has nothing to disclose.
Nicolas Roche reports grants and personal fees from Boehringer Ingelheim, Novartis and Pfizer, and personal fees from Teva, GlaxoSmithKline, AstraZeneca, Chiesi, Mundipharma, Sanofi, Sandoz, 3M and Zambon.
Anita Simonds has recently been appointed to Endpoint Invigilation Committee for Aspiro gene therapy trial in X-linked myotubular myopathy.
Vincent Cottin reports personal fees and non-financial support from Actelion, grants, personal fees and non-financial support from Boehringer Ingelheim and Roche, personal fees from Bayer/MSD, Gilead, Novartis, Sanofi, Promedior, Celgene and Galapagos.
Michael Neiderman has received research grants from Shionogi, Merck and Bayer, and consultancy fees from Shionogi, Bayer, Merck, Paratek, AstraZeneca and Pfizer.
Pierguiessepe Agostoni has received grants from Daiichi Sankyo, Actelion and Bayer, and non-financial support from Novartis, Boeringer and Actelion.
Toby Maher has, via his institution, received industry-academic funding from GlaxoSmithKline R&D and UCB and has received consultancy or speakers fees from Apellis, AstraZeneca, Bayer, Biogen Idec, Boehringer Ingelheim, Galapagos, GlaxoSmithKline R&D, Indalo, Pliant, ProMetic, Roche, Samumed and UCB.
Edmund Lau has received personal fees and research support from Actelion Pharmaceuticals and GlaxoSmithKline.
Mina Gaga has received lecture fees from AstraZeneca, BMS and MSD, as well as departmental research grants from Menarini, Becro, Galapagos and Novartis.
Robert Vassallo has been the recipient of research funding from Pfizer, Bristol-Myers-Squibb and Sun Pharmaceuticals.
Pascal Chanez provided consultancy services for Boehringer Ingelheim, Johnson & Johnson, GlaxoSmithKline, Merck Sharp & Dohme, AstraZeneca, Novartis, Teva, Chiesi, Sanofi and SNCF. He has served on advisory boards for Almirall, Boehringer Ingelheim, Johnson & Johnson, GlaxoSmithKline, AstraZeneca, Novartis, Teva, Chiesi, and Sanofi; received lecture fees from Boehringer Ingelheim, Centocor, GlaxoSmithKline, AstraZeneca, Novartis, Teva, Chiesi, Boston Scientific and ALK; and received industry-sponsored grants from Roche, Boston Scientific, Boehringer Ingelheim, Centocor, GlaxoSmithKline, AstraZeneca, ALK, Novartis, Teva and Chiesi.
Ganesh Raghu has nothing to disclose.
Rachel Chambers has received industry-academic research funding via a collaborative framework agreement from GlaxoSmithKline R&D and has received consultancy or speakers fees from GlaxoSmithKline, Roche, Theravance and Pieris Pharmaceuticals. Her spouse is a current employee of Galecto Bioscience.
Renata Riha has nothing to disclose.
Renaud Louis has received grants from GlaxoSmithKline, AstraZeneca, Novartis, Actelion, Roche and Chiesi, and advisory board fees or lectures fees from AstraZeneca, Novartis and GlaxoSmithKline.
Chakaya Muhwa nothing to disclose.
Rudolph Huber has received lecture fees and advisory board fees from Pfizer, Celgene, Takeda, Lilly, BMS, Roche and Boehringer Ingelheim. He has also served on the advisory committee for AstraZeneca, and received travel fees from Boehringer Ingelheim.
Antonella Caminati reports personal fees from Roche and Boehringer Ingelheim.
Steve Cunningham provides consultancy for the following, for which the University of Edinburgh receive payment: Boehringer Ingelheim, Janssen, Ablynx, ReViral, Pulmocide and Cystic Fibrosis Trust.
Marc Humbert reports personal fees from Actelion Pharmaceuticals Ltd/Johnson & Johnson, Arena Pharmaceuticals Ltd, Pfizer and United Therapeutics, and grants and personal fees from Bayer/Merck and GlaxoSmithKline. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. Outside pulmonary vascular medicine, M. Humbert has a research interest in severe asthma and reports personal fees from AstraZeneca, Novartis, Roche/Genentech, Sanofi/Regeneron and Teva. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards.
Bogdan Grigoriu has nothing to disclose.
Jean-Paul Sculier has nothing to disclose.
Carlos Robalo Cordeiro has received fees for national advisory committees from Novartis, AstraZeneca and GSK, fees for international advisory committees from Boehringer Ingelheim and Roche, and lecture fees from Teva and Mundipharma. He has also received educational fees from GSK, research fees from Boehringer Ingelheim and equipment from Roche.